Clinical trial
Efficacy and Safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss
Name
AM-111-CL-13-01
Description
The purpose of this research study is to test the effectiveness and safety of the study drug, AM-111. AM-111 is tested for the treatment of sudden sensorineural hearing loss where the cause is unknown.
Trial arms
Trial start
2015-11-01
Estimated PCD
2017-09-01
Trial end
2017-09-01
Status
Completed
Phase
Early phase I
Treatment
Placebo
Arms:
Placebo
AM-111 0.4 mg/ml
Arms:
AM-111 0.4 mg/ml
AM-111 0.8 mg/ml
Arms:
AM-111 0.8 mg/ml
Size
256
Primary endpoint
Pure tone average (PTA; average of the hearing threshold of three contiguous most affected hearing frequencies in dB)
Day 28
Eligibility criteria
Inclusion Criteria:
1. Unilateral ISSNHL with onset within 72 hours prior to study treatment;
2. Mean hearing threshold of equal to or worse than (≥) 60 dB averaged across the 3 most affected contiguous air conduction audiometric pure tone frequencies ("pure tone average", PTA);\*
3. Mean hearing loss of equal to or worse than (≥) 40 dB averaged across the air conducted PTA frequencies compared with the unaffected contralateral ear or reference values from a pre-existing audiogram or ISO 7029;2000 norm values in case of asymmetric hearing prior to the ISSNHL incident;
4. Age ≥ 18 and ≤ 65 years on the day of screening;
Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
1. Bilateral ISSNHL;
2. Acute hearing loss from noise trauma, barotrauma or head trauma;
3. History of autoimmune hearing loss, radiation-induced hearing loss, endolymphatic hydrops or Menière's disease in the affected ear;
4. History of chronic inflammatory or suppurative ear disease or cholesteatoma in the affected ear;
5. History of acoustic neuroma or other retrocochlear damage in the affected ear;
6. History of otosclerosis in the affected ear;
7. Suspected perilymph fistula or membrane rupture in the affected ear;
8. Congenital hearing loss;
9. History of ISSNHL in the past 2 years;
10. Otitis media or otitis externa that is ongoing or ended within 7 days prior to study treatment;
Other protocol-defined exclusion criteria may apply.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 256, 'type': 'ACTUAL'}}
Updated at
2023-09-14
1 organization
1 product
1 indication
Organization
Auris MedicalProduct
AM-111Indication
Hearing impairment